Opendata, web and dolomites

OXIFLOW SIGNED

Next Generation Flow Diverter for the Treatment of Intracranial Aneurysms Delivering Improved Patient Outcomes and Healthcare Cost Savings

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXIFLOW project word cloud

Explore the words cloud of the OXIFLOW project. It provides you a very rough idea of what is the project "OXIFLOW" about.

options    divert    nitinol    coning    addressable    ing    origami    market    fd    small    innovative    oe    central    vessels    patient    invasive    approvals    subarachnoid    minimally    regulatory    business    excellent    expectations    made    expensive    surgical    away    risk    extension    coiling    diverters    material    citizens    haemorrhage    pilot    cumulative    disabilities    restrict    procedure    severe    causes    aneurysm    utilises    weak    optimum    flow    man    porosity    mesh    vessel    reporting    freeze    thereby    shape    transfer    tortuous    ethical    safety    fim    inherent    radial    entirely    rupture    463m    each    cheaper    ias    failed    generating    ia    treatment    first    02m    56m    unruptured    apposition    live    delivering    whilst    oxiflow    natural    memory    poorer    overcoming    die    uniform    period    fds    avoidable    poor    guidewire    lower    risky    sah    inferior    endovascular    resolution    device    whom    clinical    40    principles    suffer    limitations    forces    performance    healing    51    revenues    73    clipping    manufacture    intracranial    blood    complete   

Project "OXIFLOW" data sheet

The following table provides information about the project.

Coordinator
OXFORD ENDOVASCULAR LIMITED 

Organization address
address: 9400, GARSINGTON ROAD, OXFORD
city: OXFORD
postcode: OX4 2HN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 4˙232˙828 €
 EC max contribution 2˙962˙979 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OXFORD ENDOVASCULAR LIMITED UK (OXFORD) coordinator 2˙962˙979.00

Map

 Project objective

Each year ~51,000 EU citizens suffer a subarachnoid haemorrhage (SAH) resulting from the rupture of an intracranial aneurysm (IA), of whom 40% will die and 40% will suffer severe disabilities. However, SAH’s are entirely avoidable through treatment of ‘at risk’ unruptured IAs.

Existing treatment options include: surgical clipping, an invasive, risky and expensive procedure but delivering excellent long-term resolution; and endovascular coiling, a cheaper and lower risk minimally invasive procedure but delivering poorer long-term resolution. Flow diverters (FDs) are an emerging endovascular device that divert blood flow away from the aneurysm thereby enabling natural healing. Whilst offering the potential of excellent long-term resolution at low risk and cost, existing FDs have failed to live up to expectations, reporting performance inferior to coiling. Limitations of existing FD’s are inherent to their mesh design that causes weak and non-uniform radial forces resulting in poor vessel apposition, variable porosity and device coning. Existing delivery systems also restrict use due to extension of the central guidewire during delivery.

OxiFlow is a unique FD design based on origami principles and made from a shape memory Nitinol material. The innovative design enables optimum and uniform radial forces thereby overcoming the limitations of existing FDs. Furthermore, OxiFlow utilises a novel delivery system enabling complete user control of the central guidewire extension and thus use in small and tortuous vessels.

OXIFLOW will evaluate safety and performance of the OxiFlow device through a 10-patient First-in-Man (FIM) study. Project activities include: device design freeze, transfer to pilot scale manufacture, pre-clinical testing; regulatory and ethical approvals; and FIM study implementation.

The addressable EU & US market for OxiFlow is estimated at €463M. OE target €40.02M business growth over a 5-year period generating €73.56M cumulative revenues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIFLOW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIFLOW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LiCrete (2018)

LiCrete - Light transmitting composite material for building purposes

Read More